A
Armando Santoro
Researcher at Humanitas University
Publications - 961
Citations - 56759
Armando Santoro is an academic researcher from Humanitas University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 93, co-authored 847 publications receiving 48505 citations. Previous affiliations of Armando Santoro include Aix-Marseille University & University of Milan.
Papers
More filters
Journal ArticleDOI
The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies.
Siegfried Segaert,Josep Tabernero,Olivier Chosidow,Thomas Dirschka,Joern Elsner,Luca Mancini,Tim Maughan,Jean François Morere,Armando Santoro,Alberto Sobrero,Eric Van Cutsem,Alison M. Layton +11 more
TL;DR: An overview of the treatment options for skin reactions that are available today are presented, and some of the ways in which the treatment of such EGFR‐inhibitor‐related skin reactions may be improved in the future are evaluated.
Journal ArticleDOI
Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial
Lorenza Rimassa,Armando Santoro +1 more
TL;DR: The SHARP trial has demonstrated that sorafenib is effective in prolonging median survival and time-to-progression in patients with advanced HCC and that it is generally well tolerated with a manageable adverse events profile.
Journal ArticleDOI
Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis
T. Pressiani,Corrado Boni,Lorenza Rimassa,R. Labianca,Stefano Fagiuoli,Stefania Salvagni,Daris Ferrari,Enrico Cortesi,Camillo Porta,Claudia Mucciarini,L. Latini,C. Carnaghi,Maria Banzi,Silvia Fanello,M. De Giorgio,Fabio Romano Lutman,Guido Torzilli,M. A. Tommasini,R. Ceriani,Giovanni Covini,Maria Chiara Tronconi,Laura Giordano,N. Locopo,S. Naimo,Armando Santoro +24 more
TL;DR: Data suggest that patients with CP class B liver function can tolerate treatment and may still benefit from sorafenib, although patients with HCC and CP class A liver function have poorer outcomes than those withCP class A function.
Journal ArticleDOI
Cyvadic in advanced soft tissue sarcoma: A randomized study comparing two schedules: A study of the EORTC soft tissue and bone sarcoma group
Herbert M. Pinedo,Vivien H.C. Bramwell,H. T. Mouridsen,R. Somers,C. P. J. Vendrik,Armando Santoro,J. Buesa,T. Wagener,A. van Oosterom,J. A. M. van Unnik,Richard Sylvester,M. De Pauw,D. Thomas,O. Bonadonna +13 more
TL;DR: In this paper, a large number of adults with advanced progressive soft tissue sarcoma received combination chemotherapy with cyclophosphamide, vincristine, Adriamycin (doxorubicin), and DTIC.
Journal ArticleDOI
Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma
Giovanni Luca Ceresoli,Paolo Andrea Zucali,Fabio De Vincenzo,Letizia Gianoncelli,Matteo Simonelli,Elena Lorenzi,C. Ripa,Laura Giordano,Armando Santoro +8 more
TL;DR: Re-treatment with PBC should be considered as second-line therapy in MPM patients achieving a durable (>12 months) disease control with first-line PBC.